16 results about "Cerebrospinal fluid sample" patented technology

This document provides methods and materials for assessing and / or treating subjects (e.g., humans) suspected of having cancer. For example, this document provides methods and materials for a nucleic acid sequence analysis which can determine a sequence of B cell receptor. In some cases, determining a sequence of B cell receptor (and, optionally, identifying the presence of one or more mutations and / or identifying the presence of aneuploidy) in DNA (e.g., cell-free DNA (cfDNA)) in a fluid sample (e.g., a cerebrospinal fluid sample) obtained from a subject (e.g., a human subject such as a human suspected of having cancer) can be used to identify the subject as having cancer.

The invention provides a method for rapidly determining 27 free fatty acids in cerebrospinal fluid by liquid chromatography-mass spectrometry, and belongs to the technical field of free fatty acid detection. The method comprises the following steps: dissolving three isotope internal standard substances of decanoic acid-D19, hexadecanoic acid-D9 and docosanoic acid-D4 in methanol to obtain a mixed solution for internal standard use; sequentially carrying out vortex and centrifugation on the cerebrospinal fluid sample, the internal standard mixed solution and methanol to obtain a supernatant; and detecting the supernatant by using a liquid chromatography-mass spectrometry method. According to the method, free fatty acid in a cerebrospinal fluid sample can be qualitatively and quantitatively detected at the same time, protein is efficiently extracted and precipitated, it is guaranteed that fatty acid in the cerebrospinal fluid is fully extracted, the quantitative accuracy is guaranteed, and meanwhile operation is easy and rapid.

The invention belongs to the field of biomedicine, and particularly relates to a bifunctional modified magnetic bead and an extraction method of exosomes in cerebrospinal fluid. Aiming at the defects of an existing magnetic bead capture method in the aspect of removing impure protein, the invention firstly provides a bifunctional modified magnetic bead, a CD63 antibody and a sulphobetaine type zwitterionic polymer are modified on the surface of the bifunctional modified magnetic bead, specific capture of the exosome is realized on the basis of antigen-antibody specific binding of CD63 and the exosome, and meanwhile, the adsorption effect on the impure protein is reduced. The magnetic beads are applied to extraction of exosomes in cerebrospinal fluid, and the technical defects that the sample size of the cerebrospinal fluid is small, and the recovery rate of a traditional method is not high are effectively overcome.

The application discloses a RPA-CRISPR / Cas12a-based rapid visual detection method for manning's paragonimus. The method takes the mitochondrial cox1 gene as a target, screens a conservative region through sequence alignment, designs specific crRNA and RPA primers, optimizes Cas12a, crRNA, a fluorescent reporter molecule and a buffer system, and constructs a recombinase polymerase amplification combined CRISPR / Cas12a trans-cleavage detection system. Two visual detection strategies, visual fluorescence and lateral flow chromatography, are adopted, so that instant detection can be realized without large instruments and professional personnel, and the method has the advantages of high sensitivity and good specificity, can accurately detect manning's paragonimus DNA, cat and dog feces and blood samples, and brain schistosomiasis cerebrospinal fluid samples, and is suitable for on-site rapid screening.

This invention discloses a gene biomarker panel for detecting PCNSL based on cerebrospinal fluid (cerebrospinal fluid) ctDNA, relating to the fields of gene detection and molecular diagnostics. The gene biomarker panel includes MYD88, PIM1, CD79B, GNA13, IRF4, DTX1, KMT2D, and B2M. By detecting the mutation status of these genes in a subject's cerebrospinal fluid sample, the mutation status is input into a trained random forest classification model to generate auxiliary judgment results, providing molecular evidence for diagnosing PCNSL in the subject. This eight-gene combination panel has shown high diagnostic specificity in multiple cerebrospinal fluid ctDNA-based validation cohorts and has the ability to identify MYD88 wild-type PCNSL.

The invention discloses a supramolecular fluorescent sensing array and application thereof in preparation of a preparation or a kit for early diagnosis of Alzheimer's disease, the supramolecular fluorescent sensing array comprises a plurality of sensing units, and each sensing unit is composed of a macrocyclic main solution and a fluorescent indicator solution; a macrocyclic main body used in the macrocyclic main body solution is selected from at least one of any macrocyclic main bodies; a fluorescent indicator used in the fluorescent indicator solution is selected from at least one of any fluorescent indicators. The supramolecular fluorescence sensing array can accurately distinguish cerebrospinal fluid samples of alzheimer disease transgenic rats in different disease course stages, and a new method is provided for early-stage accurate diagnosis and disease course monitoring of the alzheimer disease.

The invention discloses a method for identifying abnormal cell enrichment and invasive phenotype in cerebrospinal fluid, which comprises the pretreatment steps of centrifuging a cerebrospinal fluid sample, lysing red blood cells and resuspending a buffer solution, and inputting the pretreated cerebrospinal fluid into a microfluidic enrichment module flowing from bottom to top, intercepting the cells with relatively large volume through a single cell filtering membrane and obtaining enriched cell components; spreading or fixing the enriched cells on an imaging carrier, carrying out multi-channel fluorescent staining by adopting an epithelial marker antibody, an invasion-related marker antibody and a nuclear dye, and acquiring multi-channel microscopic image data by utilizing an imaging unit. And the invasion phenotype identification module is used for carrying out segmentation, morphological characteristic analysis and marker expression quantification on the cell image, constructing invasion phenotype parameters of abnormal cells and carrying out typing. The method provided by the invention can realize stable enrichment and objective phenotype recognition of abnormal cells in cerebrospinal fluid.

The invention relates to the technical field of inflammatory factor detection, in particular to a multi-index synchronous detection method and system for inflammatory factors related to neuroinfection, and the method comprises the following steps: collecting a cerebrospinal fluid sample, extracting initial data of the inflammatory factors, combining flow velocity and resistance to generate a positioning table, identifying a concentration interval, extracting detection parameters, and screening a rhythm deviation path; according to the method, a concentration positioning table is established through flow velocity and resistance parameters, factor state distribution is accurately identified, perception of dynamic changes is enhanced, active channels and reaction sites are extracted based on the concentration interval, the target focusing efficiency is improved, and the method is suitable for large-scale popularization and application. The channel rhythm is judged through detection speed, delay and processing speed, dynamic calibration of the path state is achieved, result coordination and linkage analysis are achieved, a closed-loop process with state perception, path registration and parameter regulation and control as the core is integrally constructed, and detection stability, synchronism and response precision are improved.

The present application relates to the technical field of detection for auxiliary diagnosis of neurological diseases, in particular to a neurological cerebrospinal fluid sampling and detecting device. The device comprises a sampling cylinder, an end cap, a piston handle, a transfusion tube and a needle. The sampling cylinder is externally provided with a back-pushing mechanism for connecting the top of the sampling cylinder with the transfusion tube. When the piston handle is drawn into the cerebrospinal fluid, the gas in the sampling cylinder is pushed into the back-pushing mechanism for storage by means of the piston handle. When the piston handle reaches a preset liquid level, a liquid supplementing area is formed between the preset liquid level and the cerebrospinal fluid level. The gas in the back-pushing mechanism is released to the end of the transfusion tube to drive the remaining liquid in the transfusion tube to be supplied into the sampling cylinder. Through the cooperation of the piston handle and the back-pushing mechanism, the gas in the sampling cylinder is first collected into the back-pushing mechanism for storage, and then the remaining liquid in the transfusion tube is pushed back into the sampling cylinder by the gas pressure in the back-pushing mechanism to fill the cerebrospinal fluid vacancy in the liquid supplementing area, thereby improving the concentration of the final cerebrospinal fluid sample and ensuring the accuracy of the detection result.

The invention discloses a cerebrospinal fluid responsibility pathogen data analysis method based on nanopore sequencing, relates to the technical field of high-throughput sequencing, biological information analysis and molecular diagnosis, and provides a method for analyzing responsibility pathogen data of cerebrospinal fluid by aiming at the problems that the cerebrospinal fluid nanopore sequencing data still contains dozens of microorganisms and the existing method is difficult to accurately judge the responsibility pathogen. The method comprises the following steps: firstly, acquiring nanopore sequencing original data of a cerebrospinal fluid sample, and analyzing and identifying microorganisms and corresponding Reads numbers through splitting, cleaning and comparison; the method comprises the following steps: introducing FPT (Fragment Per Thusand) as an abundance index, and correcting factors such as genome length and PCR (Polymerase Chain Reaction) amplification deviation; the method comprises the following steps: calculating a Normalized-FPT value on the basis of background data of a non-infected cerebrospinal fluid sample; and in combination with a biosafety level (Biosafety level), the responsibility pathogen judgment is realized. In 41 cases of cerebrospinal fluid sample metagenome sequencing analysis, the sensitivity of the method reaches 94.7% and is obviously higher than that of next-generation sequencing, the specificity reaches 100%, and responsibility pathogens of central nervous system infection can be accurately recognized; in 18 cerebrospinal fluid sample macro transcriptome sequencing analysis cases, the sensitivity of the method reaches 90%, and the specificity reaches 100%. In a word, the invention of the BAN analysis method promotes the application of nanopore sequencing in the diagnosis of the responsible pathogens of the central nervous system infection.

A method of detecting ASC specks in a patient sample generally includes labeling a patient sample of cerebrospinal fluid with an anti-ASC antibody and detecting the anti-ASC antibody, thereby detecting the ASC specks in the patient sample. The method may be used to determine the risk of the patient having a neurodegenerative disorder or an inflammatory disorder.

The invention relates to an oligonucleotide combination and kit for detecting and distinguishing cryptococcus. The oligonucleotide combination comprises a specific primer, a guide chain and a reporter probe, wherein the specific primer, the guide chain and the reporter probe are designed aiming at a cryptococcus neoformans CAP59 gene and a cryptococcus gattii GPA1 gene. The kit comprises the oligonucleotide combination, pfAgo enzyme, divalent manganese ions and a reaction buffer solution, and can be used for non-diagnostic purpose detection. The method comprises the following steps: carrying out asymmetric PCR amplification on a sample DNA to obtain a single-chain product, incubating the single-chain product with pfAgo enzyme, a guide chain and a reporter probe together to carry out a cleavage reaction, and finally distinguishing the cryptococcus species through fluorescence signals (such as FAM and ROX). The method has the advantages of high specificity and sensitivity (the lower detection limit reaches 1CFU / mL), no cross reaction, short detection time (about 60 minutes), accurate verification in clinical cerebrospinal fluid samples, and suitableness for rapid identification of cryptococcus.

The application provides a methylation marker site, a brain stem glioma typing and prognosis model, and belongs to the technical field of gene detection, comprising a plurality of methylation marker sites, a methylation model is constructed based on the methylation marker sites, and the brain stem glioma is typed by using ctDNA in cerebrospinal fluid, combining a methylation model, a model composed of a methylation model and a gene mutation. The methylation marker screened by the application has high specificity in different subtypes of BSG. The machine learning model trained by using the methylation marker has very high accuracy and specificity in combination with mutation information. The model constructed based on the above methylation marker also has high accuracy and specificity for cerebrospinal fluid samples, which provides the possibility for subsequent tumor dynamic monitoring. The prediction result of the methylation data has guiding significance for patient prognosis stratification.

The application discloses a method for constructing a precise prediction non-small cell lung cancer meningeal metastasis risk model based on cerebrospinal fluid proteins and application, and relates to the technical field of biological medicine.Combining Olink detection technology, aiming at the problems of NSCLC-LM late discovery and diagnosis difficulty, 46 NSCLC-LM patients and 40 nLM patients cerebrospinal fluid samples are collected, among which 59 cases are used as a training set to construct a risk prediction model, and 27 cases are used as a validation set to judge the model efficiency.The results show that 7 specific proteins ADA, NOS3, KDR, TGFB1, TNFRSF12A, MMP7 and CASP8 are involved in model construction, the training set AUC is 0.94, the validation set AUC is 1.00, the training set sensitivity is 0.96, the training set specificity is 0.88, the validation set sensitivity is 1.00, and the validation set specificity is 0.79.The application has great significance in the field of NSCLC-LM early diagnosis and screening.

This document provides methods and materials for assessing and / or treating subjects (e.g., humans) suspected of having cancer. For example, this document provides methods and materials for a nucleic acid sequence analysis which can determine a sequence of T cell receptor. In some cases, determining a sequence of T cell receptor (and, optionally, identifying the presence of one or more mutations and / or identifying the presence of aneuploidy) in DNA (e.g., cellular DNA and cell-free DNA (cfDNA)) in a fluid sample (e.g., a cerebrospinal fluid sample) obtained from a subject (e.g., a human subject such as a human suspected of having cancer) can be used to identify the subject as having cancer.